Poly Medicure Limited has informed the Exchange about Copy of Newspaper Publication for the Audited Financial Results (Standalone & Consolidated) for the quarter and year ended 31st March, 2026

POLYMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-12.8%1-day move

₹1520.00

prior close

₹1435.60

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.2+0.2+0.4—-12.8-11.2-12.8-13.0-11.7-6.6+1.2+8.2+10.2—

Up moveDown movePending

AI summary

Poly Medicure Limited has published its audited financial results for Q4 and FY 2025-26. Standalone total income grew 5.4% YoY to ₹1,78,238 lakh for the year, while consolidated income rose 13.4% to ₹1,99,534 lakh. However, quarterly profit declined due to an exceptional charge of ₹680.40 lakh arising from new labour code implementation. Standalone net profit after tax for the year stood at ₹33,598 lakh (vs ₹33,133 lakh prior year), with Q4 net profit at ₹8,062 lakh (vs ₹8,666 lakh). Consolidated Q4 net profit fell to ₹6,504 lakh from ₹9,183 lakh. EPS on standalone basis was ₹33.15 for the full year and ₹7.95 for Q4. The statutory auditors have issued an unmodified audit opinion.

Likely market impact

Revenue growth is positive but Q4 profit contraction due to labour code changes may create near-term pressure on the stock. The consolidated revenue surge suggests strong operational performance that could support long-term value.